Physician profile
Renee Sferra
NPI 1154569838
$1,946.82
in general payments reported to CMS, 2019-2025
13 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 91% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.89 |
| Education | $144.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $502.14 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $491.65 | 2025 | Tezspire, Breztri, Fasenra |
| Harmony Biosciences LLC | $257.08 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $106.70 | 2025 | Uptravi, Opsumit |
| Kci USA, INC. | $101.63 | 2023 | V.A.C. Veraflo |
| Viatris Specialty LLC | $76.79 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $74.56 | 2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $66.93 | 2025 | |
| Merck Sharp & Dohme LLC | $65.45 | 2025 | Zerbaxa |
| Takeda Pharmaceuticals U.S.A., INC. | $63.42 | 2025 | Glassia |
| Abbvie INC. | $62.14 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.79 | 2025 | Ofev, Jascayd |
| Amgen INC. | $38.54 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Sferra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.